Check for updates

OPEN ACCESS

EDITED BY Cristina De Angelis, University of Naples Federico II, Italy

REVIEWED BY

Marco Ghezzi, Independent Researcher, Padova, Italy Begoña Pérez-Fernández, Spanish Institute of Oceanography (IEO), Spain

*CORRESPONDENCE Shi Qiu qiushi@scu.edu.cn Qiang Wei weiqiang933@126.com

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Systems Endocrinology, a section of the journal Frontiers in Endocrinology

RECEIVED 05 September 2022 ACCEPTED 31 October 2022 PUBLISHED 07 December 2022

CITATION

Yuan Q, Jin K, Zhou X, Qiu Z, Li J, Jin D, Zhang Z, Zhang C, Yang L, Zhan Y, Qiu S and Wei Q (2022) Urinary polycyclic aromatic hydrocarbon metabolites are positively related to serum testosterone levels of males and serum estradiol levels of females among U.S. adults. *Front. Endocrinol.* 13:1037098. doi: 10.3389/fendo.2022.1037098

COPYRIGHT

© 2022 Yuan, Jin, Zhou, Qiu, Li, Jin, Zhang, Zhang, Yang, Zhan, Qiu and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Urinary polycyclic aromatic hydrocarbon metabolites are positively related to serum testosterone levels of males and serum estradiol levels of females among U.S. adults

Qiming Yuan^{1†}, Kun Jin^{1†}, Xianghong Zhou^{1†}, Zhimei Qiu², Jiakun Li¹, Di Jin¹, Zilong Zhang¹, Chichen Zhang¹, Lu Yang¹, Yu Zhan², Shi Qiu^{1*} and Qiang Wei^{1*}

¹Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China, ²Department of Environmental Science and Engineering, Sichuan University, Chengdu, Sichuan, China

Background: It has been reported for several years that polycyclic aromatic hydrocarbons (PAHs) could disturb human endocrine function. However, there is still a short of consistent conclusion about the relationship between PAH exposure and levels of sexual hormones. The aim of our study is to explore whether exposure to PAHs and how PAHs affect the levels of serum testosterone (T) and estradiol (E2) in adults, hoping to fulfill the knowledge gap.

Materials and methods: This study included adults aged 20 and above who participated in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2016. We included 10 PAH metabolites in this study. The levels of urinary PAH metabolites were log-transformed and divided into quartiles. The associations between PAH metabolites and both serum T levels of males and E2 levels of females were investigated using multivariate regression models. We furtherly calculated PAHs scores by sum of ranks across 10 PAHs metabolites, which represented the exposure levels of PAHs mixtures, and the association between PAHs scores and serum T and E2 levels were analyzed.

Results: A total of 4,654 subjects were included in this study, including 2,460 males and 2,194 females. After adjusting for confounders, 2-hydroxynapthalene and 3-hydroxyfluorene were positively associated with serum T levels of males (p-value for trend=0.047, and p-value for trend=0.006, respectively), while 1-hydroxyphenanthrene was positively associated with serum E2 levels of females (p-value for trend=0.013). In the adjusted models, no significant association was found between PAHs scores and either T levels of males or E2 levels of females (p-value for trend=0.615, and p-value for trend=0.241, respectively).

Conclusions: This study showed urinary 2-hydroxynapthalene and 3-hydroxyfluorene were associated with increased T levels of males, and urinary 1-hydroxyphenanthrene was associated with increased E2 levels of females. The observed association indicated disrupting effects of PAH exposure on reproductive health.

KEYWORDS

polycyclic aromatic hydrocarbon, testosterone, estradiol, reproductive health, national health and nutrition examination survey

Introduction

Polycyclic aromatic hydrocarbons (PAHs) are a family of environment toxin which are ubiquitous in urban atmospheres. PAHs are produced mainly by incomplete combustion of organic compounds, including diesel, gasoline, coal, oil, wood, et al. (1), and people can expose to PAHs through smoking, vehicle exhaust, industrial production, and food (2). To evaluate the exposure level of people to PAHs, previous studies mainly applied levels of urinary PAH metabolites (3–6). Studies have reported environment toxins could disturb the levels of reproductive hormone and increase the risk of relative diseases such as breast cancer (7–10). As an important environment toxin, the relationship between PAHs and people's reproductive system is under intense investigation.

Testosterone (T) as the major male sex hormone can promote the development of male reproductive tissue and spermatogenesis. The secretion of T is regulated by luteinizing hormone (LH), which is secreted at anterior pituitary responded to gonadotropin-releasing hormone (GnRH). A previous study found PAHs could disturb the balance of hypothalamicpituitary-gonadal axis, and in this study a positive association between secretion of GnRH and exposure to low-dosage PAHs was detected, which led to an increase of serum T level (11). However, another study reported that PAHs may disturb the function of Leydig cells, which are a group of cells in testis secreting T, resulting in a decrease of T in serum (12).

Estradiol (E2), as the most abundant and most active estrogen, is secreted by granulosa cells of follicles in the ovary. E2 plays an important role in regulating women's somatic and psychological health. For example, women will show increased susceptibility to nausea and motion sickness during the early (low serum E2 level) versus late follicular (high serum E2 level) phase (13, 14). One previous study found exposure to PAHs could enhance the production of reactive quinone species of endogenous estrogen, and there was a positive correlation between PAHs exposure and activation of estrogen, including E2 (15). However, another study found PAHs could decrease E2 secretion by disturbing the function of granulosa cells *via* ESR1 and GPER1 receptors (16).

Although the association between PAH exposure and people's reproductive health has aroused more and more attention, there is still a short of consistent conclusion about the relationship between PAH exposure and levels of sexual hormones. This may attribute to geographical differences, racial differences, selected PAHs biomarkers and exposure levels. In addition, as present studies mainly performed on animals or *in vitro* (17–21), studies investigating the association directly among human are still lacking. Thus, the aim of our study is to explore whether exposure to PAHs and which PAH could affect the levels of serum T and E2 in adults, hoping to fulfill the knowledge gap.

Materials and methods

Study subjects

The study subjects were selected from participants of the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2016. The NHANES is a cross-sectional survey of non-institutionalized citizens conducted by NCHS of the Centers for Disease Control and Prevention. The data of participants such as race, income status, dietary condition and medical history was collected through household interviews. Meanwhile, participants would undergo physical examination, and blood and urine would be collected at specific examination centers. All participants were given informed consents, and the NHANES protocol was approved by the National Center for Health Statistics Research Ethics Review Board. We included subjects with complete urinary PAHs metabolites levels and complete serum T and E2 levels. As there was a significant difference in sexual hormone levels between minors and adults, we only included adults aged 20 and above. Subjects using endocrine disrupting drugs were furtherly excluded. A total of 4,654 subjects were included in our study, including 2,460 males and 2,194 females. Details of inclusion and exclusion criteria were shown in Figure 1.


Urinary PAH metabolites measurement

The urine samples were collected at mobile examination center by trained professionals. After the collection, urine samples were stored at a temperature of -20°C or lower and transported to National Center for Environmental Health for analysis. The glucuronidated or sulfated OH-PAH metabolites in urine experienced enzymatic hydrolysis, extraction, and derivatization. Then the values of metabolites were measured using isotope dilution capillary gas chromatography tandem mass spectrometry (GC-MS/MS). The detailed information about detection and measurement of urine PAH metabolites was provided in the NHANES laboratory method (http://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/PAH_G_met.pdf).

We included 10 PAH metabolites in this study: 1hydroxynapthalene (1-naphthol), 2-hydroxynapthalene (2naphthol), 3-hydroxyfluorene, 2-hydroxyfluorene, 3hydroxyphenanthrene, 1-hydroxyphenanthrene, 2hydroxyphenanthrene, 1-hydroxypyrene, 9-hydroxyfluorene, and 4-hydroxyphenanthrene. These 10 PAHs metabolites are major monohydroxylated metabolites of four important PAHs, including naphthalene, fluorene, phenanthrene, and pyrene. In the NHANES database from 2011 to 2016, only these 10 metabolites were available.

Serum T and E2 measurements

The collected serum samples were stored at a temperature of -20°C or lower until they were transported to the Division of Environmental Health Laboratory Sciences for analysis. Before the quantitative analysis, serum T and E2 were dissociated from



binding proteins, extracted from sample matrix, and potentially interfering compounds were also removed. Then, serum T levels and E2 levels were measured using isotope dilution liquid chromatography tandem mass spectrometry (ID-LC-MS/MS) by the CDC (https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/ TST_H.htm).

Statistical analysis

To perform the analyses, we used EmpowerStats (http://www. empowerstats.com, X&Y Solutions, Inc., Boston, MA) and statistical software packages R (http://www.R-project.org, The R Foundation). A p value of <0.05 was considered statistically significant. The continuous variables were presented as mean ± standard deviation, and the categorical variables were presented as the frequency and its proportion. When the values of PAH metabolites were below the limit of detection, the values were reserved as the detection limit divided by the square root of two. The following categorical variables were included: race (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, Other Race), ratio of family income to poverty (<1.3, 1.3-3.5, >3.5), education level (Less than high school, High school or General educational development, Above high school), marital (Married or living with partner, Living alone), BMI (<=25, >25 and <=30, >30), comorbidity index (0, 1, 2-5), smoking (never, former, current), alcohol intake (none, moderate, heavy). The levels of 10 urinary PAH metabolites were log-transformed to acquire a normal distribution, and the geometric mean levels of creatininecorrected urinary PAH metabolites were divided into quartiles. The first quartile (lowest level) was set as the reference group, and the β-coefficient and 95% confidence interval (CI) were analyzed using linear regression model to determine whether there was a dose-response relationship between PAH exposure and serum T levels of males and E2 levels of females. P-value for trends were calculated to evaluate the statistical significance of trends. Extended models were performed to adjust covariates, including age, race, BMI, time of venipuncture, ratio of family income to poverty, education level, marital, comorbidity index, smoking, and alcohol intake. As the levels of T and E2 vary physiologically in relation to age, we furtherly performed age-stratified analysis. Subjects were divided into three groups: <40, >=40 and <60, >=60 groups. Associations between PAHs metabolites and sex hormones were tested in the three age groups separately. The association between PAHs metabolites and sex hormone binding globulin (SHBG) levels of males was also analyzed. Additionally, to investigate the association between exposure to PAHs mixtures and serum sexual hormone levels, we sorted the 10 urinary PAH metabolites from lowest to highest to create ranks separately, and PAHs scores were established by sum of ranks across 10 urinary PAH metabolites for each participant (22). High value of PAHs score signified heavy burden of exposure to PAHs mixtures. Association between PAHs scores and serum T and E2 levels were further investigated. Age-stratified analysis was also performed between PAHs scores and sex hormones.

Results

Characteristics of subjects

Demographic characteristics, serum T and E2 levels of 4,654 subjects from NHANES 2011-2016 were shown in Table 1. The mean age of male subjects was 48.88 years old, while females were 46.29. The BMI of 33.58% male subjects were over 30 kg/m², and the BMI of 41.75% female subjects were over 30 kg/m². For males, smokers, including former and current smokers, were up to 52.56% of subjects, while the percentage of females was 32.68%. The mean T and SHBG levels of male subjects were 409.29 ng/dl and 44.41 nmol/l, while the mean E2 level of female subjects was 82.91 pg/ml.

PAH metabolite levels

Table 2 showed the geometric mean and creatine-corrected mean concentration of 10 urinary PAH metabolites. Urinary 1hydroxynapthalene and 2-hydroxynapthalene metabolites accounted for almost 90% of total urinary PAH metabolites. Besides, urinary 2-hydroxyfluorene and 9-hydroxyfluorene metabolites were higher than the rest PAH metabolites.

Association between urinary PAH metabolites and serum T levels of males

The associations between 10 types of urinary PAH metabolites and serum T levels of males are shown in Table 3. In the nonadjusted model, 1-hydroxynapthalene, 2-hydroxynapthalene, 3hydroxyfluorene, 2-hydroxyfluorene, 3-hydroxyphenanthrene, and 1-hydroxypyrene were associated with increased serum T levels of males (p-value for trends were all <0.05). After adjusting for confounders, 2-hydroxynapthalene and 3-hydroxyfluorene remained positively correlated with serum T level [Bs for increasing quartiles: 0, -2.74 (95%CI -21.18 to 15.70), 0.49 (95% CI -18.65 to 19.63), 18.08 (95%CI -3.23 to 39.39), p-value for trend=0.047; and β s for increasing quartiles: 0, 1.43 (95%CI -16.92 to 19.78), -2.71 (95%CI -21.24 to 15.83), 29.13 (95%CI 5.14 to 53.12), p-value for trend=0.006, respectively]. No significant association between PAHs metabolites and SHBG was found (Supplementary Table 1). In the age-stratified analysis, 2hydroxynapthalene was positively associated with serum T levels among males aged 40-60 (p-value for trend=0.007), while the positive association was found between 3-hydroxyfluorene and serum T among males aged 20-40 (p-value for trend=0.002) (Supplementary Table 2). The correlation between PAHs scores TABLE 1 Demographic and laboratory characteristics of 4,654 subjects.

Gender	Male $(n = 2460)$	Female $(n = 219)$		
Age, year, mean (SD)	48.88 (17.52)	46.29 (17.00)		
Testosterone, ng/dl, mean (SD)	409.29 (180.01)	24.82 (22.81)		
Estradiol, pg/ml, mean (SD)	24.52 (9.59),	82.91 (383.58),		
SHBG, nmol/l, mean (SD)	44.41 (26.13)	78.19 (71.65)		
Time of venipuncture				
Aorning	1179 (47.93%)	1002 (45.67%)		
Afternoon	899 (36.54%)	813 (37.06%)		
Evening	382 (15.53%)	379 (17.27%)		
Race, n (%)				
Aexican American	330 (13.41%)	336 (15.31%)		
Other Hispanic	244 (9.92%)	277 (12.63%)		
Non-Hispanic White	955 (38.82%)	813 (37.06%)		
Ion-Hispanic Black	537 (21.83%)	413 (18.82%)		
Other Race	394 (16.02%)	355 (16.18%)		
atio of family income to poverty, n (%)				
1.3	712 (28.94%)	679 (30.95%)		
.3-3.5	1039 (42.24%)	909 (41.43%)		
3.5	709 (28.82%)	606 (27.62%)		
ducation level, n (%)				
ess than high school	595 (24.19%)	439 (20.01%)		
Iigh school or GED	556 (22.60%)	435 (19.83%)		
bove high school	1309 (53.21%)	1320 (60.16%)		
Aarital, n (%)				
farried or living with partner	1590 (64.63%)	1235 (56.29%)		
iving alone	870 (35.37%)	959 (43.71%)		
MI, n (%)				
=25	723 (29.39%)	688 (31.36%)		
25, <=30	911 (37.03%)	590 (26.89%)		
30	826 (33.58%)	916 (41.75%)		
Comorbidity index, n (%)				
	1450 (58.94%)	1354 (61.71%)		
	731 (29.72%)	647 (29.49%)		
, 3, 4, 5	279 (11.34%)	193 (8.80%)		
moking, n (%)				
lever	1167 (47.44%)	1477 (67.32%)		
ormer	864 (35.12%)	424 (19.33%)		
Current	429 (17.44%)	293 (13.35%)		
lcohol intake, n (%)				
one	1788 (72.68%)	1841 (83.91%)		
noderate	254 (10.33%)	81 (3.69%)		
leavy	418 (16.99%)	272 (12.40%)		

SD, standard deviation; GED, general educational development; BMI, body mass index, SHBG, sex hormone-binding globulin.

and serum T levels of males were shown in Table 4. In non-adjusted model, serum T levels were positively associated with PAHs score (p-value for trend=0.031). However, after adjusting for confounders, the association did not remain significant (p-value for trend=0.615). In addition, no significant association was found between PAHs scores and serum T levels of males in the three different age groups (Supplementary Table 4).

Association between urinary PAH metabolites and serum E2 levels of females

6 out of 10 urinary PAH metabolites showed liner relationships with serum E2 levels of females, including 1-hydroxynapthalene, 2hydroxynapthalene, 3-hydroxyfluorene, 2-hydroxyfluorene, 1-

Urinary exposure biomarkers	Geometric mean (95%CI)	Creatinine-corrected geometric mean (95%CI)		
1-hydroxynapthalene	1880.85 (1800.07-1965.26)	2055.58 (1973.07-2141.53)		
2-hydroxynapthalene	4984.40 (4824.23-5149.89)	5455.18 (5314.46-5599.63)		
3-hydroxyfluorene	93.68 (90.14-97.37)	102.27 (98.94-105.71)		
2-hydroxyfluorene	224.08 (216.56-231.86)	244.62 (237.91-251.52)		
3-hydroxyphenanthrene	65.71 (62.33-69.26)	70.90 (68.03-73.89)		
1-hydroxyphenanthrene	109.03 (106.17-111.95)	119.03 (116.62-121.48)		
2-hydroxyphenanthrene	66.86 (63.80-70.08)	72.08 (69.49-74.78)		
1-hydroxypyrene	120.38 (117.22-123.64)	131.51 (128.47-134.63)		
9-hydroxyfluorene	270.18 (255.95-285.19)	291.56 (279.00-304.69)		
4-hydroxyphenanthrene	21.54 (20.59-22.54)	23.23 (22.32-24.18)		

 TABLE 2 Distribution of urinary PAH metabolites among 4,654 subjects.

PAH, polycyclic aromatic hydrocarbon; CI, confidence interval.

hydroxyphenanthrene, and 1-hydroxypyrene (Table 3). In the nonadjusted model, 2-hydroxynapthalene, 2-hydroxyfluorene, 3hydroxyfluorene, and 1-hydroxyphenanthrene were positively associated with serum E2 levels (p=0.002, p=0.045, p=0.008, and p=0.034, respectively). After adjusting for confounders, 1hydroxyphenanthrene remained positively associated with serum E2 levels [ßs for increasing quartiles: 0, 1.94 (95%CI -48.71 to 52.59), 24.68 (95%CI -27.23 to 76.59), 63.94 (95%CI 7.73 to 120.14), p-value for trend=0.013]. In the age-stratified analysis, 1hydroxyphenanthrene was positively associated with serum E2 levels among females aged 20-40 (p-value for trend=0.002) (Supplementary Table 3). The correlation between PAHs scores and serum E2 levels were shown in Table 4. In non-adjusted model, serum E2 levels were positively associated with PAHs scores (pvalue for trend=0.005). Similarly, after adjusting for confounders, the association did not remain significant (p-value for trend=0.241), and no significant association was found between PAHs scores and serum E2 levels of females in three different age groups (Supplementary Table 4).

Discussion

We examined the association between urinary PAH metabolites and serum T levels of males and serum E2 levels of females separately. The results of this study showed urinary 2-hydroxynapthalene and 3-hydroxyfluorene were positively associated with serum T levels of males, and urinary 1-hydroxyphenanthrene was positively associated with serum E2 levels of females. 2-hydroxynapthalene, 3-hydroxyfluorene, and 1-hydroxyphenanthrene were major metabolites of naphthalene, fluorene, and phenanthrene respectively. This indicated exposure to naphthalene and fluorene might result in an increased level of T of males, and phenanthrene might cause the increasing of E2 level of females.

In the stratified analysis, urinary 2-hydroxynapthalene and 3-hydroxyfluorene were positively associated with serum T

levels of males aged 40-60 and 20-40 respectively, and urinary 1-hydroxyphenanthrene was positively associated with serum E2 levels of females aged 20-40. This indicated that young and middle-aged people were more sensitive to the exposure of PAHs than the elderly. PAHs scores was not significantly associated with sex hormones in the three different age groups, which was consistent with the results of total population.

Previous studies focusing on the relationship between PAH exposure and serum sexual hormone levels did not reach a consistent result. In addition, as PAHs consist of hundreds of compounds, the types of PAHs or their metabolites included in different studies were not the same, which made it more difficult to collate and compare the results of different studies. A cross-sectional study which included 371 men in an infertility clinic in Wuhan, China observed 2-hydroxynaphthalene was associated with decreased serum free T (p-value for trend=0.01) (23). However, in another study including 642 males which analyzed the associations between PAH metabolites and several different reproductive hormones, no significant correlation was found between 2hydroxynapthalene metabolites and serum T levels (24). Interestingly, we observed a positive association between urinary 2-hydroxynapthalene and serum T levels of males in our study. Similarly, results of present studies investigating the association between PAH exposure and serum E2 levels showed a divergence. One study including 120 pregnant Chinese women detected the exposure to both low-molecular-weight and high-molecular weight PAHs could negatively affect the E2 level in the umbilical cord serum (25). There were studies showed a positive association between PAHs exposure and serum E2 level. In one study including 122 non-smoker males, there was a positive association between hydroxypyrene and serum E2 levels (26). Benefiting from NHANES database, we included more kinds of PAH metabolites, and the sample size of our study was larger compared with previous studies, which made our results more systematic and reliable.

The positive association between PAHs exposure and serum T and E2 levels may be explained by several mechanisms. One study explored the association between GnRH expression and TABLE 3 Relationships between urinary PAH metabolites and sex hormones in the non-adjusted and adjusted model.

		Testosterone (ng/dl)		Estradiol (pg/ml)		
Exposure biomarkers			β (95%CI)	p-value	β (95%CI)	p-valu
1-hydroxynapthalene	Non-adjusted	Quartile 1	0		0	
		Quartile 2	-4.00 (-24.15, 16.14)	0.697	11.93 (-41.68, 65.54)	0.663
		Quartile 3	4.42 (-15.73, 24.58)	0.667	0.28 (-54.28, 54.84)	0.992
		Quartile 4	50.77 (30.62, 70.92)	< 0.001	21.09 (-33.10, 75.27)	0.446
		p-value for trend		< 0.001		0.466
	Adjusted	Quartile 1	0		0	
		Quartile 2	0.60 (-17.89, 19.09)	0.949	31.50 (-22.12, 85.12)	0.250
		Quartile 3	-6.16 (-24.98, 12.65)	0.521	31.50 (-23.96, 86.95)	0.266
		Quartile 4	10.51 (-11.95, 32.97)	0.359	32.59 (-32.53, 97.72)	0.327
		p-value for trend		0.230		0.615
2-hydroxynapthalene	Non-adjusted	Quartile 1	0		0	
		Quartile 2	-6.94 (-27.02, 13.14)	0.498	16.04 (-37.29, 69.37)	0.556
		Quartile 3	-0.38 (-20.45, 19.70)	0.971	33.41 (-19.51, 86.32)	0.216
		Quartile 4	37.98 (17.91, 58.04)	< 0.001	77.64 (24.66, 130.61)	0.004
		p-value for trend		< 0.001		0.002
	Adjusted	Quartile 1	0		0	
		Quartile 2	-2.74 (-21.18, 15.70)	0.771	-8.01 (-62.11, 46.08)	0.772
		Quartile 3	0.49 (-18.65, 19.63)	0.960	-13.66 (-69.59, 42.28)	0.632
		Quartile 4	18.08 (-3.23, 39.39)	0.096	36.56 (-23.98, 97.11)	0.237
		p-value for trend		0.047		0.141
3-hydroxyfluorene	Non-adjusted	Quartile 1			0	
, ,	,	Quartile 2	11.08 (-8.81, 30.96)	0.275	7.68 (-43.92, 59.28)	0.770
		Quartile 3	16.97 (-2.77, 36.71)	0.092	45.11 (-6.11, 96.33)	0.085
		Quartile 4	85.29 (65.49, 105.09)	< 0.001	57.03 (4.74, 109.31)	0.033
		p-value for trend		< 0.001		0.045
	Adjusted	Quartile 1	0		0	
	,	Quartile 2	1.43 (-16.92, 19.78)	0.879	-0.19 (-51.44, 51.06)	0.994
		Quartile 3	-2.71 (-21.24, 15.83)	0.775	33.57 (-17.79, 84.92)	0.200
		Quartile 4	29.13 (5.14, 53.12)	0.017	23.90 (-42.28, 90.07)	0.479
		p-value for trend		0.006		0.521
2-hydroxyfluorene	Non-adjusted	Quartile 1	0		0	
, ,	,	Quartile 2	-7.06 (-26.99, 12.87)	0.488	14.44 (-36.39, 65.27)	0.578
		Quartile 3	0.99 (-18.94, 20.93)	0.922	46.91 (-4.35, 98.18)	0.073
		Quartile 4	57.86 (37.94, 77.79)	< 0.001	72.83 (20.93, 124.74)	0.006
		p-value for trend	, , , , , , , , , ,	< 0.001		0.008
	Adjusted	Quartile 1	0		0	
)	Quartile 2	-5.78 (-24.07, 12.51)	0.536	3.43 (-47.12, 53.98)	0.894
		Quartile 3	-6.24 (-24.83, 12.36)	0.511	31.47 (-19.93, 82.87)	0.230
		Quartile 4	8.09 (-15.04, 31.23)	0.493	48.75 (-17.40, 114.90)	0.149
		p-value for trend		0.275		0.143
8-hydroxyphenanthrene	Non-adjusted	Quartile 1	0			
5-nyaroxypicitantinene		Quartile 2	5.77 (-27.59, 39.13)	0.735		
		Quartile 3	26.17 (-7.19, 59.53)	0.125		
		Quartile 4	45.21 (11.84, 78.57)	0.008		
		p-value for trend		0.004		
	Adjusted	Quartile 1	0	0.001		
	2 injuoten	Quartile 2	-9.49 (-40.79, 21.81)	0.552		

(Continued)

TABLE 3 Continued

Exposure biomarkers $β$ (95%C1) p-value $β$ (95%C1) p-value $β$ (95%C1) p-value 1-bydaoxylinandinene Non-adjustel (aurile 1 0 0.435 1-bydaoxylinandinene Non-adjustel 0 0.435 0 (aurile 1 0 0 0.435 0.435 (aurile 2 9.29 (140%, 29.44) 0.366 1.164 (22.37, 36.29) 0.691 (aurile 1 0 0 0.435 0.435 0.435 (aurile 1 0 0 0.435				Testosterone ((ng/dl)	Estradiol (pg/ml)		
Induct of the second	Exposure biomarkers			β (95%CI)	p-value	β (95%CI)	p-value	
inductorinductorinductorinductor1-biddroxphenamineneNon-adjustedQuartile 100Quartile 1926 (1038, 294, 00, 3071.729 (2.334; 00.29)0.464Quartile 3936 (1027, 20, 000)0.371.729 (2.334; 00.29)0.464Quartile 41021 (-939, 00.30)0.3671.729 (2.334; 00.29)0.464Quartile 10000Quartile 1000.0310.032Quartile 2326 (1.457, 22.01)0.68924.68 (-22.37, 65.99)0.352Quartile 31.324 (1.459, 67.31)0.6190.0160.016Quartile 40000.016Quartile 40.404 (-23.67, 57.31)0.4190.4200.4202.3ydbroxphenamitreseNon-adjustedQuartile 4000Quartile 40.404 (-23.67, 57.31)0.4190.41100Quartile 40.404 (-23.67, 57.31)0.611000Quartile 40.404 (-23.67, 57.31)0.6910.0110.0110.0111.4ydbroxypheneNon-adjustedQuartile 40.4010.4010.0110.0111.4ydbroxypheneNon-adjustedQuartile 400001.4ydbroxypheneNon-adjusted0.431 (43.67, 71.09, 0.0110.414 (43.71.09, 0.0110.414 (43.71.09, 0.0110.414 (43.71.09, 0.0110.414 (43.71.09, 0.0110.414 (43.71.09, 0.0110.414 (43.71.09, 0.0110.414 (43.67, 71.09, 0.0110.414 (43.67, 71.09, 0.011			Quartile 3	3.32 (-28.75, 35.38)	0.839			
1-hydroxythemathrenNen-adjustedQuartile 100Quartile 2929 (10.66, 0243)0.666-1.64, 6.32, 09, 49, 10, 405Quartile 410.21 (-9.39, 30.30)0.300.502 (-2.23, 10.388)0.661Quartile 40000Quartile 1000Quartile 2322 (-14.57, 22.21)0.6841.94 (-48.71, 52.91)0.690Quartile 3322 (-14.57, 22.21)0.6841.94 (-48.71, 52.91)0.690Quartile 40000Quartile 400.6150.615Quartile 40000Quartile 400.6160Quartile 40.41 (-13.58, 64.01, 0.61)0.6160Quartile 40000Quartile 40000Quartile 50.41 (-13.58, 64.01, 0.61)00Quartile 40000Quartile 50.41 (-13.58, 64.01, 0.61)00Quartile 50.41 (-13.58, 64.01, 0.61)00Quartile 4000Quartile 50.41 (-13.68, 64.01, 0.61)00Quartile 50.41 (-13.58, 64.01, 0.61)00Quartile 60.41 (-13.68, 64.01, 0.61)00Quartile 60.41 (-13.68, 64.01, 0.61)00Quartile 60.41 (-13.68, 64.01, 0.61)00Quartile 70.41 (-13.68, 64.01, 0.61)00Qu			Quartile 4	8.61 (-26.44, 43.67)	0.630			
ParticleQuartile 29.29 (-10.36, 29.44)0.366-1.46 (-52.09, 49.18)0.935Quartile 30.362 (-10.27, 30.00)0.37717.92 (-3.34, 6.6.29)0.604Quartile 410.21 (-2.9.39, 30.03)0.30717.92 (-3.34, 6.6.29)0.604P-alue for trend000Quartile 33.32 (-14.57, 22.21)0.6461.94 (-4.97, 1.20, 1.0026)Quartile 4-0.104 (-2.994, 2.8.38)0.2076.5.91 (7.3, 120, 1.4)0.026Quartile 32.36 (-10.27, 37, 35, 1.0)0.165			p-value for trend		0.455			
9,0000116 3 9,86 (-1027, 5000) 0,37 17.92 (-3.34, 69.29) 0.04 4,000016 102 (-9.39, 03.24) 0,302 0.52 (-2.39, 10.38, 0.001 4,000001 0 0 0 2,000011 0 0 0 2,000011 0.21 (-19.89, 17.21) 0.89 24.68 (-2.52, 10.28, 0.00) 0.026 2,000011 0.001 0.001 0.001 0.001 0.001 2,000011 0.001 0.001 0.001 0.001 0.001 2,000011 0 0.001 0.001 0.001 0.001 0.001 2,000011 0 0.001 <td>1-hydroxyphenanthrene</td> <td>Non-adjusted</td> <td>Quartile 1</td> <td>0</td> <td></td> <td>0</td> <td></td>	1-hydroxyphenanthrene	Non-adjusted	Quartile 1	0		0		
Adjustel Qurile'a			Quartile 2	9.29 (-10.86, 29.44)	0.366	-1.46 (-52.09, 49.18)	0.955	
p-value for trend0.4640.034Quartile 100Quartile 23.82 (14.57, 22.21)0.6841.94 (-48.71, 52.59)0.940Quartile 3-1.32 (19.88), 17.24)0.6841.94 (-48.71, 52.59)0.935Quartile 4-10.49 (29.82, 8.83)0.2876.394 (.7.31, 120.14)0.026p-value for trend0.01670.0170.013Quartile 20.276, 57.57, 31)0.1650.0140.014Quartile 20.276, 57.57, 31)0.1650.0170.017Quartile 30.281 (19.69, 47.31)0.0450.0170.017Quartile 40.241 (12.35, 52.04)0.0370.0160.017Quartile 30.281 (12.56, 38.11)0.6990.0170.011Quartile 40.241 (23.57, 62.49, 41.17)0.0110.01010.0111-hydroxypyreneNon-adjuatedQuartile 1000Quartile 10000.0170.0110.0111-hydroxypyreneNon-adjuatedQuartile 22.842, 48.33)0.6011.812 (1.44, 67, 67.10, 68.05)0.500Quartile 20.285 (156.85, 85.69)0.0011.812 (1.44, 67.71, 0.067)0.5000.007Quartile 30.243 (50.48, 90.38)-0.0010.6000.077Quartile 40.43 (50.48, 90.38)-0.0010.444 (4.29, 10.12)0.072Quartile 40.43 (50.48, 90.38)-0.0010.444 (4.29, 10.12)0.072Quartile 100000 <t< td=""><td></td><td></td><td>Quartile 3</td><td>9.86 (-10.27, 30.00)</td><td>0.337</td><td>17.92 (-33.45, 69.29)</td><td>0.494</td></t<>			Quartile 3	9.86 (-10.27, 30.00)	0.337	17.92 (-33.45, 69.29)	0.494	
AdjustedQuartile 100Quartile 23.02 (445,7, 22.21)0.6893.44 (62.27, 32.23)0.320Quartile 31.32 (49.98, 17.93)0.2076.394 (7.73, 12.014)0.020P-valae forterid000Quartile 22.576 (9.78, 57.31)0.1650Quartile 31.381 (49.69, 47.53)0.1610Quartile 40.496 (9.27, 37.20)0.4150Quartile 30.312 (19.69, 47.53)0.4150Quartile 40.406 (12.75, 47.64)0.4350Quartile 40.407 (12.75, 47.64)0.4350Quartile 40.404 (-11.25, 52.04)0.4370Quartile 40.404 (-11.25, 52.04)0.4370Quartile 40.410 (-1.55, 52.04)0.4370.437Quartile 40.410 (-1.55, 52.04)0.4370.437Quartile 40.412, 52.52.04)0.4370.437Quartile 40.412, 52.52.04)0.4370.437Quartile 40.412, 62.53, 63.310.4390.437Quartile 40.412, 62.54, 63.310.4310.437Quartile 40.413, 63.49, 63.910.444, 63.49, 63.910.434Quartile 40.414, 63.05, 63.710.4410.444, 63.49, 63.910.431Quartile 40.414, 63.05, 63.710.4310.444, 63.49, 63.910.431Quartile 40.414, 63.05, 63.710.4310.444, 63.49, 63.910.431Quartile 50.4164, 10.45, 63.770.4160.444, 63.49, 63.910.41			Quartile 4	10.21 (-9.93, 30.34)	0.320	50.82 (-2.231, 103.88)	0.061	
Partial sector of the sector			p-value for trend		0.446		0.034	
Quartile 3-1.32 (-19.89, 17.24)0.89924.68 (-27.23, 76.59)0.352Quartile 4-0.40 (-29.82, 8.83)0.28763.94 (7.73, 120.14)0.006p-valae fortered-00.013Quartile 100Quartile 223.76 (-57.8, 73.1)0.165Quartile 313.14 (-19.69, 47.31)0.49Quartile 416.14 (-17.36, 49.64)0.34Quartile 70.401 (-12.3, 52.46)0.361Quartile 70.401 (-12.3, 52.46)0.67Quartile 70.401 (-12.3, 52.46)0.679Quartile 70.431 (-3.46, 71.06)0.564Quartile 70.433 (-3.46, 48.33)0.00515.47 (-37.10, 68.05)P-12/04 forter 100Quartile 70.431 (-3.46, 71.09)0.502Quartile 70.431 (-3.46, 71.09)0.502Quartile 70.431 (-3.46, 71.09)0.502Quartile 70.431 (-3.46, 72.10, 68.05)0.564Quartile 7000Quartile 70.431 (-3.46, 72.10, 68.05)0.564Quartile 7000Quartile 70.510.51Quartile 70.510.51Quartile 70.510.51Quartile 70.510.51Quartile 70.520.51Quar		Adjusted	Quartile 1	0		0		
Particle(Jourile 2)(Jourile 2) </td <td></td> <td></td> <td>Quartile 2</td> <td>3.82 (-14.57, 22.21)</td> <td>0.684</td> <td>1.94 (-48.71, 52.59)</td> <td>0.940</td>			Quartile 2	3.82 (-14.57, 22.21)	0.684	1.94 (-48.71, 52.59)	0.940	
2-hydroxyphenanthrene Non-adjusted Quartile 0 Quartile 2 Quartile 3)381 (1989, 47.31) 0.163 Quartile 3)381 (1989, 47.31) 0.419 Quartile 3)3181 (1989, 47.31) 0.419 Quartile 4)0 Quartile 4)0 Quartile 0 Quartile 0 Quartile 0 Quartile 0 Quartile 2 Quartile 2 Quartile 2 Quartile 2 Quartile 2 Quartile 2)0 (0 (11.23, 52.04) 0.207 Quartile 3)0 (207 Quartile 3)0 (207 Quartile 2)0 (207 Quartile 3)0 (207 Quart			Quartile 3	-1.32 (-19.89, 17.24)	0.889	24.68 (-27.23, 76.59)	0.352	
2-hydroxyphenanthreneNon-adjustedQuartile 10Quartile 227,67 (9,78, 57,31)0,16Quartile 313,14 (19,69,47,31)0,419Quartile 416,14 (17,36,94,40)0,345Pavlae for treet0,637Quartile 40,14 (1,23,52,04)0,207Quartile 30,204 (12,3,52,04)0,207Quartile 47,34 (26,49,41,17)0,671Pavlae for treet00Quartile 36,28 (25,55, 38,11)0,591Pavlae for treet00Quartile 47,4 (26,49,41,17)0,671Quartile 50,237 (84,2,48,33)0,05115,47 (3,71,0,60,50)0,564Quartile 7000Quartile 70,20118,21 (34,67,71,09)0,500Quartile 70,2010,3161,547 (3,71,0,60,50)0,500Quartile 70,316000Quartile 70,416 (0,46,0,40,30)0,60118,21 (34,67,71,09)0,500Quartile 70,216000Quartile 70,216 (34,61,30)0,6140,514 (34,71,09)0,500Quartile 70,216 (34,04,04,03)0,6141,544 (14,24,61,61)0,500Quartile 70,216 (34,04,04,03)0,6141,544 (14,24,61,61)0,500Quartile 70,216 (34,04,04,04,04,04,04,04,04,04,04,04,04,04			Quartile 4	-10.49 (-29.82, 8.83)	0.287	63.94 (7.73, 120.14)	0.026	
quarile 2Quarile 2Q376 (+978, 57.31)0.165Quarile 313.81 (-19.69, 47.31)0.119P-value for 100.637P-value for 100.637Quarile 10Quarile 20.404 (-11.23, 52.04)0.677Quarile 30.282 (-25.56, 38.11)0.697Quarile 47.42 (-26.9, 41.17)0.671Quarile 47.42 (-26.9, 41.17)0.671P-value for treat0.9850Quarile 47.42 (-26.9, 41.17)0.671Quarile 47.42 (-26.9, 41.17)0.671Quarile 500Quarile 47.42 (-26.9, 41.17)0.671Quarile 47.42 (-26.9, 41.17)0.671Quarile 500Quarile 47.42 (-26.9, 41.17)0.671Quarile 5000Quarile 47.42 (-26.9, 41.17)0.670Quarile 50.643 (15.65, 56.00)0.1011.521 (-34.67, 71.09)Quarile 47.42 (-26.8, 57.60)0.6010Quarile 50.283 (50.46, 90.38)-0.010Quarile 6000Quarile 70.251 (-26.27, 57.16)0.616P-value for treat000Quarile 70.263 (-26.27, 74.21)0.626P-value for treat000Quarile 82.494 (-34.6, 28.63)0.666P-value for treat000Quarile 90.284 (-34.6, 28.63)0.661P-value for treat000			p-value for trend		0.167		0.013	
quili 3 quili 4	2-hydroxyphenanthrene	Non-adjusted	Quartile 1	0				
number inductionnumber inductionnumber inductionnumber inductionAdjustedinductioninductioninductionAdjustedinductioninductioninductionAdjustedinduction			Quartile 2	23.76 (-9.78, 57.31)	0.165			
p-value for trend0.637AdjustedQuartile 10Quartile 20.40 (-11.23, S2.04)0.207Quartile 20.40 (-11.23, S2.04)0.207Quartile 36.28 (-25.56, 38.11)0.667q-value for trend0.9850.067p-value for trend0.000515.47 (-37.10, 68.05)0.540Quartile 100Quartile 228.37 (84.24.84.33)0.00515.47 (-37.10, 68.05)0.500Quartile 40.043 (50.48, 90.85)<0.001			Quartile 3	13.81 (-19.69, 47.31)	0.419			
AjustelisolateisolateisolateAjustel00.000Quarita 20.000 (-11,20,204)0.000Quarita 20.200 (-20,204,94,17)0.601Quarita 20.200 (-20,204,94,17)0.601Pauseo T0.0000.000Quarita 20.200 (-20,204,94,01)0.000Quarita 20.200 (-20,204,94,01)0.000Quarita 20.200 (-20,204,04,01)0.001Quarita 20.200 (-20,204,04,01)0.001Quarita 20.200 (-20,204,04,02)0.001Quarita 20.200 (-20,204,04,02)0.001Quarita 20.200 (-20,204,04,02)0.001Quarita 20.200 (-20,204,04,02)0.010Quarita 20.200 (-20,204,04,02)0.010Quarita 20.200 (-20,204,04,02)0.010Quarita 20.200 (-20,204,04,02)0.010Quarita 20.200 (-20,204,04,02)0.010Quarita 30.200 (-20,204,04,02)0.010Quarita 40.200 (-20,204,04,02)0.010Quarita 40.200 (-20,204,04,02)0.020Quarita 4 </td <td></td> <td></td> <td>Quartile 4</td> <td>16.14 (-17.36, 49.64)</td> <td>0.345</td> <td></td> <td></td>			Quartile 4	16.14 (-17.36, 49.64)	0.345			
AdjustedQuartile 10Quartile 220.40 (-11.23, 52.04)0.207Quartile 36.28 (-25.63, 81.1)0.699Quartile 47.34 (-26.49, 41.17)0.671Pavlae for term00Quartile 100Quartile 228.37 (8.42, 48.33)0.00515.47 (-37.10, 68.05)0.564Quartile 338.64 (18.68, 58.60)-0.0118.21 (-34.67, 71.99)0.500Quartile 470.43 (50.48, 90.38)-0.0148.46 (-4.29, 10.12)0.072Quartile 538.64 (18.68, 58.60)-0.0118.21 (-34.67, 71.99)0.500Quartile 470.43 (50.48, 90.38)-0.0148.46 (-4.29, 10.12)0.072Pavlae for term0Quartile 100-0Quartile 218.46 (0.06, 56.87)0.04-5.40 (-46.88, 57.67)0.840Quartile 10-0-0Quartile 218.46 (0.06, 56.87)0.04-5.40 (-46.88, 57.67)0.840Quartile 10-0-0Quartile 218.46 (0.06, 56.87)0.0419.54 (-41.24, 76.63)0.502Pavlae for term0-0Quartile 325.15 (-5.27, 31.42.1)0.260Quartile 40.20 (-29.27, 37.66)0.866Quartile 50.261Quartile 6Quartile 70.284 (p-value for trend		0.637			
Non-adjustedQaurili 2 Quarili 3 Quarili 4 Quarili 3 Quarili 4 Quarili 3 Quarili 4 Quarili 4 Quaril		Adjusted	*	0				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$,			0.207			
India of the second s			-					
1-hydroxypyreneNon-adjusted $p-value for trend0.9851-hydroxypyreneNon-adjustedQuartile 100Quartile 228.37 (8.42, 48.33)0.00515.47 (-37.10, 68.05)0.564Quartile 338.64 (18.68, 58.60)<0.00118.21 (-34.67, 71.09)0.500Quartile 470.43 (50.48, 90.38)<0.00148.46 (-4.29, 101.21)0.072p-value for trend<000148.46 (-4.29, 101.21)0.072p-value for trend<000148.46 (-4.29, 101.21)0.072Quartile 1000Quartile 218.46 (0.06, 36.87)0.0495.40 (-46.88, 57.67)0.840Quartile 323.49 (4.80, 42.19)0.014-0.44 (-37.54, 52.73)0.870Quartile 425.51 (52.84, 45.75)0.0149.54 (-41.24, 76.63)0.520p-value for trend0000Quartile 3-19.26 (52.73, 14.21)0.260-10Quartile 3-19.26 (52.73, 14.21)0.261-10Quartile 42.83 (-20.44, 46.303)0.453-10Quartile 3-19.26 (52.73, 14.21)0.261-10Quartile 40.201 (-54.67, 23.84, 33.843)0.860-10Quartile 10-12-14.24-14.24Quartile 2-2.84 (-54.63, 13.63)0.261-14.24Quartile 3$								
1-hydroxypyrene Non-adjusted Quartile 1 0 0 1-hydroxypyrene Non-adjusted Quartile 2 $28,37$ ($8,42$, $48,33$) 0.05 $15,47$ ($-37,10$, $68,05$) 0.564 Quartile 3 $38,64$ ($18,68, 58,60$) -001 $18,21$ ($-34,67,71,09$) 0.500 Quartile 4 $70,43$ ($50,48, 90,38$) -001 0021 0.688 Adjusted Quartile 1 0 0 0021 Quartile 2 $18,46$ ($0.06, 36, 87$) 0.049 5.40 ($-46, 88, 57, 67$) 0.806 Quartile 3 $23,49$ ($480, 42,19$) 0.014 -9.44 ($-37, 54, 52, 73$) 0.897 9-hydroxyfluorene Non-adjusted Quartile 1 0 -9.202			-					
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1-hvdroxvpvrene	Non-adjusted	-	0		0		
9.4.1Quartile 338.64 (18.68, 58.60)<0.001		,			0.005		0.564	
Quartile 4 70.43 50.48, 90.38) <0.001								
n-value for trend <0.001 0.068 Adjusted Quartile 1 0 0 Quartile 2 18.46 (0.06, 36.87) 0.049 5.40 (-46.88, 57.67) 0.840 Quartile 3 23.49 (4.80, 42.19) 0.014 -0.44 (-37.54, 52.73) 0.987 Quartile 4 25.51 (5.28, 45.75) 0.014 19.54 (-41.24, 76.63) 0.502 9-hydroxyfluorene Non-adjusted Quartile 1 0 0 0495 9-hydroxyfluorene Non-adjusted Quartile 1 0 0.453 0.453 9-hydroxyfluorene Non-adjusted Quartile 1 0 0.453 0.453 Quartile 4 12.83 (-20.64, 46.30) 0.453 0.453 0.453 0.453 P-value for trend 0 0 0.411 0 0.411 0.4			-					
AdjustedQuartile 100Quartile 218.46 (0.06, 36.87)0.0495.40 (-46.88, 57.67)0.840Quartile 323.49 (4.80, 42.19)0.014-0.44 (-37.54, 52.73)0.987Quartile 425.51 (5.28, 45.75)0.01419.54 (-41.24, 76.63)0.502p-value for trend0000Quartile 24.20 (-29.27, 37.66)0.8060.495Quartile 3-19.26 (-52.73, 14.21)0.2600.495Quartile 412.83 (-20.64, 46.30)0.4530.453p-value for trend0.3940.3940.394Quartile 2-2.84 (-34.36, 28.68)0.8600.4616Quartile 3-18.40 (-50.43, 13.63)0.2610.261Quartile 43.26 (-31.93, 38.44)0.8560.7184-hydroxyphenanthreneNon-adjustedQuartile 10Non-adjustedQuartile 100Quartile 2-2.142 (-54.86, 12.01)0.210Quartile 3-21.16 (-54.60, 12.28)0.215			-					
4.hydroxyphenanthrene Non-adjusted Quartile 2 18.46 (0.06, 36.87) 0.049 5.40 (-46.88, 57.67) 0.840 9-hydroxyphenanthrene Non-adjusted Quartile 2 18.46 (0.06, 36.87) 0.014 -0.44 (-37.54, 52.73) 0.987 9-hydroxyfluorene Non-adjusted Quartile 2 25.51 (5.28, 45.75) 0.014 19.54 (-41.24, 76.63) 0.502 9-hydroxyfluorene Non-adjusted Quartile 1 0 0 0.495 9-hydroxyfluorene Non-adjusted Quartile 2 4.20 (-29.27, 37.66) 0.806 0.495 Quartile 3 -19.26 (-52.73, 14.21) 0.260 0.495 0.495 0.495 Quartile 4 12.83 (-20.64, 46.30) 0.453 0.495 0.496 <td></td> <td>Adjusted</td> <td>·</td> <td>0</td> <td></td> <td>0</td> <td></td>		Adjusted	·	0		0		
Quartile 323.49 (4.80, 42.19)0.014-0.44 (-37,54, 52.73)0.987Quartile 425.51 (5.28, 45.75)0.01419.54 (-41.24, 76.63)0.502p-value for trent00.0520.495Quartile 1000.806Quartile 24.20 (-29.27, 37.66)0.8060.806Quartile 3-19.26 (-52.73, 14.21)0.2600.934Quartile 400.9340.9340.934AdjustedQuartile 1000.934Quartile 2-2.84 (-34.36, 28.68)0.8600.8060.934Quartile 3-0.431, 31.63)0.2610.9340.934AdjustedQuartile 1000Quartile 43.26 (-31.93, 38.44)0.8560.936Aurtile 100004.hydroxyphenanthreneNon-adjustedQuartile 10Quartile 2-2.142 (-54.86, 12.01)0.2100.210Quartile 3-2.116 (-54.60, 12.28)0.2150.915		Tujuotou			0.049		0.840	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								
p-value for trend 0.052 0.495 9-hydroxyfluorene Non-adjusted Quartile 1 0 0 Quartile 2 4.20 (-29.27, 37.66) 0.806 0.495 Quartile 3 -19.26 (-52.73, 14.21) 0.260 0.453 P-value for trend 12.83 (-20.64, 46.30) 0.453 p-value for trend 0 0 0 Adjusted Quartile 1 0 0 Quartile 3 -18.40 (-50.43, 13.63) 0.261 0 Quartile 4 3.26 (-31.93, 38.44) 0.856 0.718 4-hydroxyphenanthrene Non-adjusted Quartile 1 0 0 Quartile 2 -21.42 (-54.86, 12.01) 0.215 0.215			-					
9-hydroxyfluorene Non-adjusted Quartile 1 0 Quartile 2 4.20 (-29.27, 37.66) 0.806 Quartile 3 -19.26 (-52.73, 14.21) 0.260 Quartile 4 12.83 (-20.64, 46.30) 0.453 p-value for trend 0 0 Quartile 1 0 0 Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 -18.40 (-50.43, 13.63) 0.261 Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0 Poule for trend 0 0 Quartile 1 0 0 Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0 p-value for trend 0 0 Quartile 1 0 0 Quartile 2 0 0.210 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215			-	20101 (0120, 10170)		19101 (11121, 90100)		
AutorQuartile 24.20 (-29.27, 37.66)0.806Quartile 3-19.26 (-52.73, 14.21)0.260Quartile 412.83 (-20.64, 46.30)0.453p-value for trend0Quartile 2-2.84 (-34.36, 28.68)0.860Quartile 2-2.84 (-34.36, 28.68)0.860Quartile 3-18.40 (-50.43, 13.63)0.261Quartile 43.26 (-31.93, 38.44)0.856p-value for trend00Quartile 2-21.42 (-54.86, 12.01)0.210Quartile 2-21.42 (-54.60, 12.28)0.215	9-hvdroxyfluorene	Non-adjusted		0				
Quartile 3 -19.26 (-52.73, 14.21) 0.260 Quartile 4 12.83 (-20.64, 46.30) 0.453 p-value for trend 0.394 Quartile 1 0 Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 -18.40 (-50.43, 13.63) 0.261 Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0 Quartile 2 0 0 Quartile 3 0 0 Quartile 4 0 0.856 p-value for trend 0 0 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215					0.806			
Quartile 4 12.83 (-20.64, 46.30) 0.453 p-value for trent 0 Quartile 1 0 Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 -18.40 (-50.43, 13.63) 0.261 quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trent 0 0 quartile 1 0 0 quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.42 (-54.66, 12.28) 0.215								
p-value for trend 0.394 Adjusted 0 Quartile 1 0 Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 -18.40 (-50.43, 13.63) 0.261 Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0 Quartile 1 0 0.718 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215								
Adjusted Quartile 1 0 Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 -18.40 (-50.43, 13.63) 0.261 Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215				12.03 (20.01, 10.00)				
Quartile 2 -2.84 (-34.36, 28.68) 0.860 Quartile 3 -18.40 (-50.43, 13.63) 0.261 Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215		Adjusted	*	0	0.071			
Quartile 3 -18.40 (-50.43, 13.63) 0.261 Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0.718 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215		Aufusteu			0.860			
4-hydroxyphenanthrene Non-adjusted Quartile 4 3.26 (-31.93, 38.44) 0.856 p-value for trend 0 0.718 Quartile 1 0 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215								
4-hydroxyphenanthrene Non-adjusted p-value for trend 0.718 Quartile 1 0 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215								
4-hydroxyphenanthrene Non-adjusted Quartile 1 0 Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215				5.20 (51.95, 50.TT)				
Quartile 2 -21.42 (-54.86, 12.01) 0.210 Quartile 3 -21.16 (-54.60, 12.28) 0.215	4-bydrovyphenanthrene	Non-adjusted	*	0	0./10			
Quartile 3 -21.16 (-54.60, 12.28) 0.215	r nyeroxypicitantillelle	mon-aujusteu			0.210			
Quartue 4 -12.05 (-43.43, 21.36) 0.480								
			Qualtile 4	-12.03 (~43.43, 21.30)	0.400			

(Continued)

TABLE 3 Continued

		Testosterone (Testosterone (ng/dl)		Estradiol (pg/ml)	
Exposure biomarkers		β (95%CI)	p-value	β (95%CI)	p-value	
	p-value for tre	nd	0.788			
Adjusted	Quartile 1	0				
	Quartile 2	-12.16 (-43.21, 18.89)	0.443			
	Quartile 3	-15.84 (-47.05, 15.37)	0.320			
	Quartile 4	-15.76 (-49.27, 17.75)	0.357			
	p-value for tre	nd	0.457			

Adjusted model: adjusted for age, race, BMI, time of venipuncture, ratio of family income to poverty, education level, marital, comorbidity index, smoking, and alcohol intake. CI, confidence interval.

TABLE 4 Relationships between PAHs scores and sex hormones in the non-adjusted and adjusted model.

PAH scores group	Testosterone, ng/dl Non-adjusted β (95%CI)	p-value	Adjusted β (95%CI)	p-value	Estradiol, pg/ml Non-adjusted β (95%CI)	p-value	Adjusted ε β (95%CI)	p-value
Group 1	0		0		0		0	
Group 2	-4.97 (-25.03, 15.09)	0.627	-0.17 (-19.99, 19.65)	0.987	18.69 (-31.56, 68.94)	0.466	23.00 (-32.88, 78.88)	0.420
Group 3	-16.28 (-36.33, 3.78)	0.112	-11.69 (-33.21, 9.84)	0.287	21.15 (-29.46, 71.77)	0.413	9.03 (-55.44, 73.50)	0.784
Group 4	26.22 (6.16, 46.28)	0.010	-2.99 (-28.14, 22.16)	0.816	82.72 (28.46, 136.97)	0.003	64.85 (-19.90, 149.60) 0.134
p-value for trend		0.031		0.615		0.005		0.241

Adjusted model: adjusted for age, race, BMI, time of venipuncture, ratio of family income to poverty, education level, marital, comorbidity index, smoking, and alcohol intake. CI, confidence interval.

short-term benzo(a)pyrene (one type of PAH) exposure, which showed benzo(a)pyrene was positively associated with GnRH by increased the mRNA expression of GnRH2 and GnRH3 (27). This indicated some kinds of PAHs could promote the secretion of GnRH, and furtherly promote the secretion of LT and T. Another study explored the alteration of sex hormone by PAH in rats and a significant increase of LH was observed after exposing to PAHs. In this study, serum T levels were decreased during PAH exposure, while T levels were gradually increased within 48 hours after the exposure. At 72h, the T levels were higher than control group (28). This could be explained by that remaining vital Leydig cells conducted a compensatory synthesis and release of T, and this likely be another reason why PAH metabolites were positively associated with serum T in our study. The positive association between PAHs exposure and serum E2 levels can also be explained by the hypothalamicpituitary-gonadal axis. Previous studies reported exposure to PAHs was related to increased levels of FSH and LH (24), which could furtherly lead to an increase of serum E2 levels. The monohydroxy derivatives of some PAHs have similar structures

with 17β -estradiol, and some of the PAH metabolites can interact with estrogen receptors, demonstrating anti-estrogenic activity (29). This can lead to an increased secretion of E2 to maintain the normal functions of estrogenic hormones.

Our study still has some limitations. First, given the characteristics of cross-sectional design, we cannot make any conclusion about causal link between PAH exposure and serum T and E2 levels. Second, as an observational study, although a number of covariates have been adjusted, unmeasured confounding factors still cannot be excluded. Third, as the half-life of PAHs are short, the urinary PAH metabolites show a within-subject variability over time, which may result in a slight difference from the actual exposure levels (30).

In conclusion, association between PAHs exposure and sex hormones varied by specific PAHs. This study showed urinary 2hydroxynapthalene and 3-hydroxyfluorene were associated with increased T levels of males, and urinary 1-hydroxyphenanthrene was associated with increased E2 levels of females. The observed association indicated disrupting effects of PAH exposure on reproductive health.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://wwwn.cdc.gov/nchs/nhanes/ default.aspx.

Ethics statement

The studies involving human participants were reviewed and approved by the National Center for Health Statistics Research Ethics Review Board. The patients/participants provided their written informed consent to participate in this study.

Author contributions

QY: Data analysis, Manuscript writing. KJ: Data analysis, Manuscript writing. XZ: Data management, Data analysis. ZQ: Data collection and management. JL: Data collection and management. DJ: Data curation, Validation. ZZ Data collection. CZ: Data collection. LY: Manuscript editing. YZ: Manuscript editing. SQ: Project development, Manuscript editing. QW: Project development, Manuscript authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National key research and development program of China (Grant No. 2017YFC0908003), National Natural Science Foundation of China (Grant No.81902578, 81974098), China Postdoctoral Science Foundation (2017M612971), Post-doctoral Science Research Foundation of

References

1. Larsen RK3rd, Baker JE. Source apportionment of polycyclic aromatic hydrocarbons in the urban atmosphere: a comparison of three methods. *Environ Sci Technol* (2003) 37(9):1873–81. doi: 10.1021/es0206184

2. Ramesh A, Walker SA, Hood DB, Guillén MD, Schneider K, Weyand EH. Bioavailability and risk assessment of orally ingested polycyclic aromatic hydrocarbons. *Int J Toxicol* (2004) 23(5):301–33. doi: 10.1080/10915810490517063

3. Best EA, Juarez-Colunga E, James K, LeBlanc WG, Serdar B. Biomarkers of exposure to polycyclic aromatic hydrocarbons and cognitive function among elderly in the united states (National health and nutrition examination survey: 2001-2002). *PloS One* (2016) 11(2):e0147632. doi: 10.1371/journal.pone.0147632

4. Chou CW, Chen YY, Wang CC, Kao TW, Wu CJ, Chen YJ, et al. Urinary biomarkers of polycyclic aromatic hydrocarbons and the association with hearing threshold shifts in the united states adults. *Environ Sci pollut Res Int* (2020) 27 (1):562–70. doi: 10.1007/s11356-019-06883-4

5. Xu C, Liu Q, Liang J, Weng Z, Xu J, Jiang Z, et al. Urinary biomarkers of polycyclic aromatic hydrocarbons and their associations with liver function in adolescents. *Environ pollut* (2021) 278:116842. doi: 10.1016/j.envpol.2021.116842

Sichuan University (2020SCU12041), Post-Doctor Research Project, West China Hospital, Sichuan University (2018HXBH085), National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Z2018C01).

Acknowledgments

The authors gratefully thank Dr. Changzhong Chen, Chi Chen, and Xin-Lin Chen (EmpowerStats X&Y Solutions, Inc., Boston, MA) for providing statistical methodology consultation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fendo.2022.1037098/full#supplementary-material

6. Lee TW, Kim DH, Ryu JY. Association between urinary polycyclic aromatic hydrocarbons and hypertension in the Korean population: data from the second Korean national environmental health survey (2012-2014). *Sci Rep* (2020) 10 (1):17142. doi: 10.1038/s41598-020-74353-w

7. Levine H, Jørgensen N, Martino-Andrade A, Mendiola J, Weksler-Derri D, Mindlis I, et al. Temporal trends in sperm count: a systematic review and metaregression analysis. *Hum Reprod Update* (2017) 23(6):646–59. doi: 10.1093/ humupd/dmx022

8. Mima M, Greenwald D, Ohlander S. Environmental toxins and Male fertility. *Curr Urol Rep* (2018) 19(7):50. doi: 10.1007/s11934-018-0804-1

9. Krzastek SC, Farhi J, Gray M, Smith RP. Impact of environmental toxin exposure on male fertility potential. *Transl Androl Urol* (2020) 9(6):2797–813. doi: 10.21037/tau-20-685

10. Bonner MR, Han D, Nie J, Rogerson P, Vena JE, Muti P, et al. Breast cancer risk and exposure in early life to polycyclic aromatic hydrocarbons using total suspended particulates as a proxy measure. *Cancer Epidemiol Biomarkers Prev* (2005) 14(1):53-60. doi: 10.1158/1055-9965.53.14.1

11. Evanson M, Van Der Kraak GJ. Stimulatory effects of selected PAHs on testosterone production in goldfish and rainbow trout and possible mechanisms of action. *Comp Biochem Physiol C Toxicol Pharmacol* (2001) 130(2):249–58. doi: 10.1016/s1532-0456(01)00246-0

12. Chung JY, Kim YJ, Kim JY, Lee SG, Park JE, Kim WR, et al. Benzo[a]pyrene reduces testosterone production in rat leydig cells *via* a direct disturbance of testicular steroidogenic machinery. *Environ Health Perspect* (2011) 119(11):1569–74. doi: 10.1289/ehp.1003391

13. Motta-Mena NV, Puts DA. Endocrinology of human female sexuality, mating, and reproductive behavior. *Horm Behav* (2017) 91:19–35. doi: 10.1016/j.yhbeh.2016.11.012

14. Rieder JK, Darabos K, Weierich MR. Estradiol and women's health: Considering the role of estradiol as a marker in behavioral medicine. *Int J Behav Med* (2020) 27(3):294–304. doi: 10.1007/s12529-019-09820-4

15. Lin C, Chen DR, Wang SL, Hsieh WC, Yu WF, Wang TW, et al. Cumulative body burdens of polycyclic aromatic hydrocarbons associated with estrogen bioactivation in pregnant women: Protein adducts as biomarkers of exposure. *J Environ Sci Health A Tox Hazard Subst Environ Eng* (2014) 49(6):634–40. doi: 10.1080/10934529.2014.865416

16. Zajda K, Gregoraszczuk EL. Environmental polycyclic aromatic hydrocarbons mixture, in human blood levels, decreased oestradiol secretion by granulosa cells *via* ESR1 and GPER1 but not ESR2 receptor. *Hum Exp Toxicol* (2020) 39(3):276–89. doi: 10.1177/0960327119886027

17. Madeen EP, Williams DE. Environmental PAH exposure and male idiopathic infertility: A review on early life exposures and adult diagnosis. *Rev Environ Health* (2017) 32(1-2):73–81. doi: 10.1515/reveh-2016-0045

18. Xia Y, Zhu P, Han Y, Lu C, Wang S, Gu A, et al. Urinary metabolites of polycyclic aromatic hydrocarbons in relation to idiopathic male infertility. *Hum Reprod* (2009) 24(5):1067–74. doi: 10.1093/humrep/dep006

19. Izawa H, Kohara M, Watanabe G, Taya K, Sagai M. Diesel exhaust particle toxicity on spermatogenesis in the mouse is aryl hydrocarbon receptor dependent. *J Reprod Dev* (2007) 53(5):1069–78. doi: 10.1262/jrd.19025

20. de Campos MF, Lo Nostro FL, Da Cuña RH, Moreira RG. Endocrine disruption of phenanthrene in the protogynous dusky grouper epinephelus marginatus (Serranidae: Perciformes). *Gen Comp Endocrinol* (2018) 257:255–63. doi: 10.1016/j.ygcen.2017.06.020

21. Kennedy CJ, Smyth KR. Disruption of the rainbow trout reproductive endocrine axis by the polycyclic aromatic hydrocarbon benzo[a]pyrene. *Gen Comp Endocrinol* (2015) 219:102–11. doi: 10.1016/j.ygcen.2015.03.013

22. Guo J, Huang Y, Bian S, Zhao C, Jin Y, Yu D, et al. Associations of urinary polycyclic aromatic hydrocarbons with bone mass density and osteoporosis in U.S. adults, NHANES 2005-2010. *Environ pollut* (2018) 240:209–18. doi: 10.1016/j.envpol.2018.04.108

23. Yang P, Sun H, Gong YJ, Wang YX, Liu C, Chen YJ, et al. Repeated measures of urinary polycyclic aromatic hydrocarbon metabolites in relation to altered reproductive hormones: A cross-sectional study in China. *Int J Hyg Environ Health* (2017) 220(8):1340–6. doi: 10.1016/j.ijheh.2017.09.004

24. Han Y, Xia Y, Zhu P, Qiao S, Zhao R, Jin N, et al. Reproductive hormones in relation to polycyclic aromatic hydrocarbon (PAH) metabolites among non-occupational exposure of males. *Sci Total Environ* (2010) 408(4):768–73. doi: 10.1016/j.scitotenv.2009.11.021

25. Yin S, Tang M, Chen F, Li T, Liu W. Environmental exposure to polycyclic aromatic hydrocarbons (PAHs): The correlation with and impact on reproductive hormones in umbilical cord serum. *Environ pollut* (2017) 220(Pt B):1429–37. doi: 10.1016/j.envpol.2016.10.090

26. Sancini A, Montuori L, Chighine A, Caciari T, Giubilati R, Sacco C, et al. Urinary hydroxypyrene and estradiol in an occupationally exposed "outdoor" population. *Ann Ig* (2014) 26(4):311–20. doi: 10.7416/ai.2014.1991

27. Wang W, Chen J, Fang Y, Wang B, Zou Q, Wang L, et al. Identification of gnrh2 and gnrh3 and their expression during brood pouch growth and short-term benzo(a)pyrene exposure in lined seahorse (Hippocampus erectus). *Comp Biochem Physiol C Toxicol Pharmacol* (2019) 225:108579. doi: 10.1016/j.cbpc.2019.108579

28. Jeng HA, Yu L. Alteration of sperm quality and hormone levels by polycyclic aromatic hydrocarbons on airborne particulate particles. *J Environ Sci Health A Tox Hazard Subst Environ Eng* (2008) 43(7):675–81. doi: 10.1080/10934520801959815

29. Arcaro KF, O'Keefe PW, Yang Y, Clayton W, Gierthy JF. Antiestrogenicity of environmental polycyclic aromatic hydrocarbons in human breast cancer cells. *Toxicology* (1999) 133(2-3):115–27. doi: 10.1016/s0300-483x(99)00018-9

30. Li Z, Romanoff LC, Lewin MD, Porter EN, Trinidad DA, Needham LL, et al. Variability of urinary concentrations of polycyclic aromatic hydrocarbon metabolite in general population and comparison of spot, first-morning, and 24-h void sampling. J Expo Sci Environ Epidemiol (2010) 20(6):526–35. doi: 10.1038/jes.2009.41